After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...
The FDA declared the shortage of Novo Nordisk's weight-loss drugs over, giving compounders until May to stop making ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...
The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...
Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...
Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the ...
Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has ...
The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results